Joan Reibman
Pulmonary Disease · New York, NYNPI 1265649933
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $70,091 of the $73,324 with a category attached, or 95.6%. AstraZeneca accounts for 89.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $29,349 and has fallen 96.3% since, to $1,074 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $1110.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$66K
- Novartis$5K
- Astrazeneca AB$3K
- Regeneron Healthcare Solutions, Inc.$46
Across 41 payments — averaging $5338.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$156K
- Astrazeneca AB$37K
- Novartis$20K
- Teva Pharmaceuticals USA, Inc.$6K
What the payments were for
- Consulting fees$70,09196%
- Speaking & faculty fees$3000%
- Travel & lodging$1,9593%
- Food & beverage$9121%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $65,748 |
| Novartis | 2 | $4,576 |
| Astrazeneca AB | 1 | $2,954 |
| Regeneron Healthcare Solutions, Inc. | 1 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$51,183
How this compares
$73,324 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 18 | $70,988 |
| NucalaMepolizumab | 15 | $57,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $32,475 |
| XolairOmalizumab | 18 | $31,486 |
| Spiriva RespimatTiotropium Bromide | 42 | $26,486 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $18,190 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $11,671 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 49 | $9,147 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $7,708 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $7,313 |
| DuleraMometasone/Formoterol | 16 | $6,032 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 159 | $4,885 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,530 |
| Fluticasone Propionate | 88 | $1,052 |
| Azelastine Hcl | 26 | $1,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSymbicort | $65,748 | $18,19055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.